UCB Gets US FDA Approval for Psoriasis Drug
By Helena Smolak
UCB received approval from the U.S. Food and Drug Administration for a drug to treat severe plaque psoriasis for which the company expects global peak annual sales of at least 4 billion euros ($4.23 billion).
The Belgian biopharmaceutical firm said Wednesday that its bimekizumab drug, which will be commercialized as Bimzelx, was approved by the FDA as a treatment for the skin disease psoriasis in adults.
"With bimekizumab now approved for psoriasis, we will move forward rapidly to submit applications for additional indications in the U.S.", it said.
The FDA approval was backed by data from three Phase 3 studies, the company said.
UCB on Tuesday said the FDA approved its Zilbrysq for the treatment of adults with myasthenia, an autoimmune disorder.
Write to Helena Smolak at helena.smolak@wsj.com
(END) Dow Jones Newswires
October 18, 2023 11:21 ET (15:21 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software